NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
NervGen Pharma Corp (OTCQX: NGENF)
NGENF Technical Analysis
4
As on 8th Jan 2025 NGENF STOCK Price closed @ 2.11 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.58 & Strong Buy for SHORT-TERM with Stoploss of 1.27 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NGENFSTOCK Price
Open | 2.10 | Change | Price | % |
High | 2.12 | 1 Day | 0.16 | 8.21 |
Low | 2.09 | 1 Week | 0.34 | 19.21 |
Close | 2.11 | 1 Month | 0.21 | 11.05 |
Volume | 3974 | 1 Year | 0.91 | 75.83 |
52 Week High 2.82 | 52 Week Low 1.17 |
OTCQX USA Most Active Stocks
KRRGF | 4.83 | 2.33% |
FCUUF | 0.52 | -20.00% |
ZNOG | 0.14 | -6.67% |
ETHE | 27.50 | -3.34% |
GBTC | 64.76 | -5.74% |
EMHTF | 0.04 | 33.33% |
SHIEF | 0.04 | 0.00% |
GTBIF | 8.95 | 14.74% |
BABYF | 0.02 | -33.33% |
TRSSF | 2.19 | -0.90% |
OTCQX USA Top Gainers Stocks
OTCQX USA Top Losers Stocks
NGENF Daily Charts |
NGENF Intraday Charts |
Whats New @ Bazaartrend |
NGENF Free Analysis |
|
NGENF Important Levels Intraday
RESISTANCE | 2.17 |
RESISTANCE | 2.15 |
RESISTANCE | 2.14 |
RESISTANCE | 2.13 |
SUPPORT | 2.09 |
SUPPORT | 2.08 |
SUPPORT | 2.07 |
SUPPORT | 2.05 |
NGENF Forecast April 2025
4th UP Forecast | 2.34 |
3rd UP Forecast | 2.27 |
2nd UP Forecast | 2.22 |
1st UP Forecast | 2.18 |
1st DOWN Forecast | 2.04 |
2nd DOWN Forecast | 2 |
3rd DOWN Forecast | 1.95 |
4th DOWN Forecast | 1.88 |
NGENF Weekly Forecast
4th UP Forecast | 2.24 |
3rd UP Forecast | 2.20 |
2nd UP Forecast | 2.17 |
1st UP Forecast | 2.15 |
1st DOWN Forecast | 2.07 |
2nd DOWN Forecast | 2.05 |
3rd DOWN Forecast | 2.02 |
4th DOWN Forecast | 1.98 |
NGENF Forecast2025
4th UP Forecast | 5.64 |
3rd UP Forecast | 4.51 |
2nd UP Forecast | 3.81 |
1st UP Forecast | 3.11 |
1st DOWN Forecast | 1.11 |
2nd DOWN Forecast | 0.41 |
3rd DOWN Forecast | -0.29 |
4th DOWN Forecast | -1.42 |
NervGen Pharma Corp ( OTCQX USA Symbol : NGENF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NGENF Other Details
Segment | EQ | |
Market Capital | 89320320.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
NGENF Address
![]() |
NGENF Latest News
NGENF Business Profile
NervGen Pharma Corp., a clinical stage biotech company, discovers and develops treatments for patients suffering from medical conditions related to nerve damage. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada. Address: Three Bentall Centre, Vancouver, BC, Canada, V7X 1J1
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service